Pharmaceuticals

Biologics CDMO Market Outlook 2026–2030: Key Business Drivers and Trends

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics cdmo market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Biologics CDMO Market by the end of 2030?

The biologics cdmo market has experienced rapid expansion over recent years. Its projected growth is from $24.15 billion in 2025 to $27.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.1%. This historical growth has been driven by factors such as the increasing biologics research, innovations in cell culture technologies, the rising incidence of chronic diseases, the expansion of biosimilar pipelines, and government backing for biopharma manufacturing.

The biologics cdmo market is anticipated to show significant expansion in the next few years. It is projected to achieve a value of $48.07 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.9%. This expansion during the forecast period is driven by various factors such as a rise in gene and cell therapy development, the integration of automation and robotics into CDMO processes, an increase in global biologics manufacturing capacity, greater investment in precision medicine, and the increasing need for cost-effective biologics. Prominent trends for the forecast period include the broadening of biologics cdmo services, increased mammalian cell-based production, a rise in the outsourcing of gene therapy manufacturing, the implementation of advanced bioprocessing techniques, and the growing demand for biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Drivers Are Shaping Future Opportunities In The Biologics CDMO Market?

The escalating demand for cell and genetic therapy is projected to fuel the expansion of the biologic CDMO market moving forward. These therapies represent innovative medical approaches that utilize living cells or genetic material to address the root causes of diseases at a cellular or genetic level, potentially treating conditions that are challenging to manage or currently incurable with traditional pharmaceuticals. The demand for cell and gene therapy is increasing due to their promise in offering groundbreaking treatments for diseases by targeting their underlying genetic or cellular origins. Biologic CDMOs provide crucial expertise in handling living cells, viral vectors, and genetic material, which facilitates the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating complex regulatory requirements and technical challenges, thereby streamlining the translation from research to clinical application. For example, in March 2024, as reported by the IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies surged to $5.9 billion in 2023, reflecting an increase of 38% from 2022. Thus, the significant rise in demand for cell and genetic therapy is a primary driver behind the growth of the biologic CDMO market.

Which Segments Are Gaining Traction In The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

What Trends Are Reshaping The Dynamics Of The Biologics CDMO Market?

Leading companies active in the biologics CDMO market are creating advanced technological solutions, such as new cell lines, to improve biopharmaceutical development and manufacturing effectiveness and capacities. This technology generates therapeutic antibodies with enhanced potency, addressing obstacles in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing entity focused on the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without sacrificing other performance attributes. This innovation helps resolve immunotherapy research and development challenges related to the demand for more potent antibody therapeutics. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from the initial discovery stage through to commercial manufacturing.

Who Are The Major Companies Operating In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologics CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795